PHARMA

PHARMA

Pharmaceutical Hydrogenation Membrane in Canada

Catalytic hydrogenation is a critical step in active pharmaceutical ingredient (API) synthesis. Canada's Hydrogen Strategy positions the country as a major hydrogen producer and exporter.

Market Context

Canada

Policy

Hydrogen Strategy for Canada

H₂ Target

Net-zero hydrogen economy by 2050, near-term industrial decarbonization

3

Cities

4

Industries

Ultra-Clean Hydrogen Source

Electrolytic hydrogen from water splitting is inherently free of carbon monoxide, sulfur, and hydrocarbon impurities that can poison precious metal hydrogenation catalysts used in API manufacturing.

GMP-Compatible On-Site Generation

On-site electrolysis provides a controlled, traceable hydrogen source that simplifies GMP documentation and qualification versus multi-sourced delivered gas.

Batch-Flexible Operation

Pharmaceutical manufacturing operates in batches. IONZERA's high wettability supports start-stop operation, generating hydrogen only when hydrogenation reactors require it.

Pharmaceutical Hydrogenation in Canada’s Hydrogen Market

Canada's Hydrogen Strategy positions the country as a major hydrogen producer and exporter. Alberta's oil and gas expertise is pivoting toward clean hydrogen, while British Columbia leverages hydropower for green electrolysis. Calgary and Edmonton are emerging as hydrogen technology and deployment hubs.

IONZERA supports Canadian hydrogen ambitions with a high-performance membrane that improves electrolysis efficiency, helping Canadian projects compete in the global clean hydrogen market.

Oil & Gas TransitionMiningAmmonia ExportHydropower-to-H2
3x

Lower Resistance

20%

Thinner Profile

PERFORMANCE ADVANTAGE

Why IONZERA for Pharmaceutical Hydrogenation in Canada

Electrolytic hydrogen from water splitting is inherently free of carbon monoxide, sulfur, and hydrocarbon impurities that can poison precious metal hydrogenation catalysts used in API manufacturing.

Shipping & Logistics

Air freight from India to Calgary/Vancouver in 6-8 business days.

Area Resistance

3x LOWER
Area Specific Resistance ComparisonIONZERA0.09-0.1 Ω·cm²Zirfon0.30 Ω·cm²00.10.20.3 Ω·cm²~3x Lower

Thickness

20% THINNER
Membrane Thickness ComparisonIONZERA350-410 μmZirfon500 μm500 μm scale20-30%thinnerThinner membrane = More compact stacks= Higher power density

Pharmaceutical Hydrogenation Membrane in Canada Cities

Frequently Asked Questions

Why choose IONZERA for pharmaceutical hydrogenation in Canada?

IONZERA delivers 3x lower ionic resistance than Zirfon, making it ideal for pharmaceutical hydrogenation applications in Canada. IONZERA supports Canadian hydrogen ambitions with a high-performance membrane that improves electrolysis efficiency, helping Canadian projects compete in the global clean hydrogen market.

How does IONZERA fit Canada's hydrogen strategy?

IONZERA's high-efficiency membrane supports both Alberta's blue-to-green hydrogen transition and BC's hydropower-based green electrolysis by reducing per-kg production costs through lower membrane resistance.

Ready to Start

Request Pharmaceutical Hydrogenation Samples for Canada

Contact G-Hexa for IONZERA pharmaceutical hydrogenation membrane samples, technical specifications, and volume pricing for Canada-based projects.

Request Sample